Industry: Healthcare
Published Date: January-2024
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 187
Report ID: PMRREP33914
The global hadron therapy market is forecasted to expand at a CAGR of 10.7% and thereby increase from a value of US$ 5,111.3 million in 2023 to US$ 10,412.7 million by the end of 2030.
|
Attributes |
Key Insights |
|
Hadron Therapy Market Size (2023E) |
US$ 5,111.3 Million |
|
Projected Market Value (2030F) |
US$ 10,412.7 Million |
|
Global Market Growth Rate (2023 to 2030) |
10.7% CAGR |
|
Historical Market Growth Rate (2018 to 2022) |
7.8% CAGR |
|
Revenue Share of Top Four Countries (2022E) |
45% |
Tumours can be targeted more precisely due to ongoing advancements in beam delivery systems, which include scanning and spot-scanning approaches. This makes it easier to modify the dosage to fit the contours of the tumour while causing the least harm to the surrounding healthy tissues. The cutting-edge method known as intensity-modulated hadron therapy (IMHT) enables the particle beams' intensity to change while a patient receives treatment. This technique reduces the impact on normal tissues and optimizes the dose distribution, giving the patient more control over treatment. Using real-time imaging technologies, including MRI and cone-beam CT, with Hadron Therapy equipment enables more precise visualisation of the tumour and surrounding structures while the patient receives treatment. This makes adaptive treatment planning easier and guarantees accurate targeting through therapy.
IGHT allows for continuous monitoring and treatment modification based on the tumour's present location by combining real-time imaging with treatment delivery. This technology improves the accuracy of hadron therapy, particularly when there is organ motion. As the biological effects of particle beams on tumours and normal tissues are considered, biological treatment planning has advanced. Customised treatment plans result from this approach, which considers the unique qualities of each patient. Advancements in particle accelerator technology enhance Hadron Therapy's dependability and efficiency. It is being investigated if compact and affordable accelerator designs could increase the accessibility of hadron therapy in many medical contexts. Hadron Therapy can be administered more precisely and consistently using automation and robots in therapy delivery systems. Error-free therapy is made more effective by automated positioning and control systems.
Increasing Incidence of Cancer to Drive Market Growth
The ageing populations, changing lifestyles, exposure to the environment, and genetic predispositions are some of the factors that have contributed to the steady rise in cancer incidence worldwide throughout time. Effective and focused treatment options are becoming more and more necessary as the number of cancer diagnoses rises. Hadron therapy, which includes carbon and proton ion therapy, is very useful in treating some cancer types that are difficult to treat with traditional treatments. Hadron Therapy's accuracy is advantageous for tumours situated in or close to sensitive areas, such as the brain or spinal cord, increasing demand for this specialised treatment. Hadron Therapy is particularly useful in the treatment of paediatric malignancies, where it is essential to limit radiation exposure to healthy tissues in order to avoid long-term negative effects. Hadron Therapy is becoming a more popular therapeutic option for paediatric oncology due in part to the rising incidence of cancer in children.
In addition, Hadron Therapy has the benefit of minimising harm to surrounding healthy tissues, which reduces treatment-related morbidity. Patients and healthcare professionals alike are becoming more conscious of the significance of reducing side effects and enhancing quality of life both during and after treatment as the number of cancer cases rises. The increasing focus on personalized and precision medicine in cancer treatment matches the potential of Hadron Therapy. Customising the course of treatment to the unique features of each patient's tumour improves the effectiveness of the treatment, and this tendency helps explain why Hadron Therapy is becoming more and more popular. Because of improvements in cancer screening programs, tumors are now more often detected early on, enabling more focused and efficient interventions. With its capacity to target tumours precisely, hadron therapy emerges as a useful element of the all-encompassing cancer care continuum.
High Initial Capital Investment
Completing the construction of a facility that satisfies the strict specifications for housing specialised equipment, radiation shielding, and patient safety is costly when building a dedicated centre for Hadron Therapy. An important portion of the total capital investment comprises these building costs. Proton and carbon ion therapy systems are among the sophisticated particle therapy equipment that must be purchased. This represents a significant portion of the original capital investment. Due to their high cost, providers and healthcare institutions may need help paying for these specialized machines. Organizations that invest in the advancement of Hadron Therapy may have to pay high research and development costs to advance patient outcomes, treatment methods, and equipment. These expenses add to the total investment and might hinder the progress of certain facilities.
Technical Challenges and Equipment Availability
The unique physical characteristics of particle beams in hadron therapy necessitate careful planning of the course of treatment. The intricacy of treatment planning presents difficulties regarding the knowledge, experience, and time required to optimize treatment parameters. One of the main technical challenges is the development of sophisticated beam delivery systems for precise tumour targeting. Continuous technological improvement is needed to provide precise and effective delivery of particle beams while minimising exposure to healthy tissues. Access to Hadron Therapy varies greatly throughout the world. Establishing and upkeep Hadron Therapy centres may be easier for high-income nations, but countries with low or middle incomes find it more difficult to get and maintain this technology.
Integration with Multidisciplinary Cancer Care
Hadron Therapy is a useful complement to other treatment methods like immunotherapy, chemotherapy, and surgery in multidisciplinary cancer care programmes. More efficient and individualized treatment programs that are suited to each patient's requirements are made possible by this all-encompassing approach. The best order for cancer patients' therapies can be ascertained by interdisciplinary teams working together. Hadron therapy can be selectively added during a patient's treatment regimen to optimize therapeutic outcomes due to its accuracy and decreased adverse effects. Hadron Therapy can be more effective when combined with other forms of treatment. Combining various therapeutic modalities may synergistically enhance overall treatment outcomes, particularly for complicated and challenging-to-treat malignancies.
Moreover, Hadron Therapy can strategically target areas where conventional treatments might be less effective or to manage residual disease. Hadron Therapy is incorporated into the multidisciplinary care plan to enable a more thorough and focused approach to cancer therapy. Hadron Therapy's fewer side effects and better treatment results help cancer patients live longer and feel better. Integrating with multidisciplinary care guarantees a patient-centered approach that considers the patient's general health and the effectiveness of the therapy. Clinical trials and ongoing research activities can more easily use Hadron Therapy thanks to multidisciplinary cancer care. This partnership makes it possible to continuously assess how well Hadron therapy works in a range of clinical settings and patient demographics.
What do our Analysts Predict for the Future of Hadron Therapy Market?
According to PMR, technological advancements in hadron therapy are anticipated to improve the accuracy and efficacy of cancer treatment, namely in particle accelerators and treatment planning systems. Improvements in patient outcomes and fewer adverse effects are made possible by advancements in dosage monitoring technology, imaging methods, and beam delivery systems. The market dynamics are also significantly influenced by the growing usage of Hadron Therapy. Healthcare providers are likely to incorporate Hadron Therapy into their cancer treatment procedures as awareness of its benefits grows, including its capacity to target tumors more precisely while sparing healthy tissues. Innovation is also expected to be driven by alliances and collaborations between academic institutions, healthcare providers, and business leaders. These partnerships can speed up research and development, which could identify fresh uses for hadron beams in cancer treatment and increase the market's potential. Geographically speaking, the market for haven therapy is anticipated to rise significantly in the Asia-Pacific area. This is explained by the region's expanding healthcare system and an increase in the number of cancer cases. The adoption of Hadron Therapy in this region is expected to be driven by the need for more advanced cancer treatment options.
Supply-side Dynamics
Europe has spearheaded research and development related to hadron treatment. Some of the world's first and most advanced hadron therapy centres are located in nations including Belgium, Germany, Italy, and Switzerland. Belgium's Louvain-la-Neuve is home to IBA Proton Therapy, a renowned producer of proton therapy accelerators. Germany's Klinikum Westfalen in Gelsenkirchen opened its doors in 1997 as the first proton therapy facility in the world. Another well-known facility that uses carbon ions for treatment is the Heidelberg Ion Therapy Centre (HIT). Italy, a leader in carbon and proton ion therapy, the Centro Nazionale di Oncological Hadronterapia (CNAO) in Pavia, is a pioneer. Switzerland, Hadron treatment technology research and development are the main priorities of the Paul Scherrer Institute (PSI) in Villigen. With more than 40 operational centers, the US boasts the most hadron therapy facilities globally.
Additionally, globally, most patients receiving hadron therapy are treated at this leader of about 41 proton therapy centers. As a result, there will be a large investment in technology, a well-established infrastructure, and high awareness. With Germany (15 centres) and Italy (3 centres) being the two largest providers, Europe is home to about 19 centres. Consumption is influenced by robust healthcare systems and the increasing use of cutting-edge cancer treatments. Japan contains about 17 centers, demonstrating early uptake and ongoing carbon and proton ion treatment developments. The placement of emphasis on R&D strengthens its position even more.
Which Type Are Expected to Benefit the Most from Revenue Generation?
Proton Beam Category Due to Growing Precise Tumor Targeting
The type segment is segmented into electron beam, proton beam, neutron beam, carbon ion beam, alpha particle beam, and beta particle beam. The proton beam segment is expected to dominate the market. Highly accurate tumour targeting is made possible by proton beam therapy. Protons' special physical characteristics minimise damage to nearby healthy tissues and organs by enabling greater control over the depth of radiation delivery. Tumours close to important structures benefit greatly from this precision. Nonetheless, the electron beam segment of the hadron therapy market is expanding at the quickest rate. Because it is important to reduce radiation exposure to healthy tissues, pediatric oncology frequently uses electron beam therapy. Electrons are useful in treating children's malignancies because of their precise, controllable penetration depth.
What Application Will Be Targeted the Most Category?
Highest Percent Share Attributed to For Pediatric Cancer Owing to Reduced Radiation Exposure to Healthy Tissues
The application segment is bifurcated into for pediatric cancer, for bone & soft tissue cancer, for prostate cancer, for lung cancer, for liver cancer, for eye cancer, for head & neck cancer. The for pediatric cancer market segment is the largest for hadron therapy. This is because central and peripheral lung tumors respond well to hadron therapy. Treating tumors on the lungs' periphery or next to important structures is beneficial when preserving healthy tissues. Nevertheless, the market segment exhibiting the most rapid growth is for lung cancer. Analog Hadron Therapy is compatible with existing Analog infrastructure, which is still prevalent in many older buildings and systems. This compatibility allows for easy integration without the need for extensive upgrades.
Which Area of End User Should Be Focused on the Most Regarding Sales?
In Hospitals Gauging End User Due to Increasing Specialized Treatment Facilities
The end user segment is sub-segmented into in hospitals, in government universities, in research institutions. In Hospitals represents the greatest market segment for the hadron therapy industry. Hadron therapy necessitates specialised facilities with cutting-edge technology, such as particle accelerators like synchrotrons or cyclotrons. These specialized centers at hospitals serve as hubs for delivering hadron therapy. On the contrary, research institutions are the market segment characterized by the most rapid growth. Leading research institutes are at the forefront of creating and optimising technology for hadron therapy. This includes developments in imaging technology, treatment planning software, particle accelerators, and other areas essential to efficiently administering hadron therapy.
Why is North America Emerging as a Dominating Region?
Rising Patient Demand for Advanced Therapies to Drive Market Growth
Advanced cancer treatment alternatives, such as hadron therapy, are becoming more well-known to patients in North America. More knowledge allows patients to ask for and find cutting-edge treatments with fewer adverse effects and better results. Patients are looking for more targeted and accurate treatments that minimise damage to adjacent healthy tissues while precisely targeting tumours. Because more precise treatments are desired, the capacity of Hadron Therapy to deliver highly focused radiation is in line with requirements. One major aspect influencing patient demand is the focus on reducing adverse effects connected to therapy. Hadron Therapy is a desirable alternative for people looking for treatments with fewer side effects because it can lower the risk of long-term consequences when compared to conventional radiation therapies.
What Opportunities Lie in Europe for Manufacturers?
Government Initiatives and Investments
Governments frequently make investments in the development of healthcare infrastructure. Financing for developing and growing medical facilities, including centers for Hadron Therapy, improves access to cutting-edge cancer therapies. Funds pertaining to Hadron Therapy research and development may be allotted by governments. This funding encourages creativity, technical development, and the investigation of novel uses for hadron therapy in the area. Governments may lead in or assist in creating centers devoted to hadron therapy. These facilities play a crucial role in providing all-encompassing cancer care and help to fulfil the rising demand for cutting-edge treatments. The cost burden for healthcare providers investing in Hadron Therapy infrastructure can greatly decrease by offering financial incentives and subsidies. These rewards motivate institutions and private companies to get involved in constructing facilities for proton therapy.
Prominent organizations, including IBA Worldwide and Varian Medical Systems, Inc., are at the vanguard of this sector; IBA Worldwide, a prominent participant in the Hadron Therapy industry, mainly concentrated on proton therapy solutions, employs a diverse approach to sustain its competitive advantage and propel expansion. A full-scale, adaptable proton therapy system designed to meet the needs of big hospitals and treatment facilities. Provides sophisticated features such as multi-room installations and pencil beam scanning. A modest, one-room option that's perfect for emerging markets or smaller facilities. Provides affordability and simplicity of installation. Creates patented software for optimising dose distribution, patient positioning, and treatment planning. Provides dosimetry equipment to measure radiation accurately. Provides scalable solutions to meet the various needs of various healthcare institutions. Aggressively investigates developing markets such as China and India while concentrating on creating a solid foothold in developed regions such as North America and Europe. Establishes strategic alliances with academic institutions, technological companies, and healthcare associations to boost innovation and expand market penetration.
Proton treatment solutions may be easily promoted and integrated into radiotherapy centers across the globe because of Varian's extensive network of existing relationships. By integrating proton therapy with its extensive radiotherapy portfolio, Varian can give clients a wider choice of cancer treatment alternatives. Varian's radiation oncology technology and knowledge can be simplified and adjusted for use with proton therapy. With two primary proton treatment systems to suit varying needs and facility sizes, Varian provides the adaptable ProBeam SuperSuite and the small ProBeam Compact system. Varian strongly emphasizes cutting-edge technology, such as adaptive therapy protocols that allow for real-time dosage adjustment, tumor tracking, and pencil beam scanning, providing precise dose delivery. Varian is continually looking for ways to lower the high expense of proton therapy equipment and treatments to increase accessibility for a larger range of patients.
New Product Launch
Hitachi announced in February 2022 that the Shonan Kamakura Advanced Medical Centre had installed its small proton therapy system and that, as of January 31, 2022, patients had been receiving treatment using the device. It is the first order for Hitachi's specialized compact proton therapy system.
Market Impact: Hitachi's technology may gain further traction in the medical center market due to this effective first installation of a specialized compact system. Because compact systems are more economical and space-efficient than typical systems, they can treat a larger range of patients and hospitals, particularly in areas with limited space. This installation provides Hitachi with useful information and input, enabling them to develop their compact system further and produce even more effective and efficient treatments.
The acquisition of Varian Medical Systems, Inc. was finalised by Siemens Healthineers in April 2021. August 2, 2020, was the day the acquisition was revealed. Siemens Healthineers offers significant wealth generation opportunities because it has the most extensive portfolio in the MedTech space with Varian. The combined business provides a distinctive, highly integrated range of laboratory diagnostics, imaging, artificial intelligence, and cancer treatment options for the worldwide cancer epidemic, with substantial opportunities to boost value development.
Market Impact: Siemens Healthineers emerged as a significant force in the worldwide MedTech industry, with the broadest range of imaging, artificial intelligence, diagnostic, and treatment technologies. Increased ability to negotiate with healthcare providers and suppliers. Improved capacities for cross-platform innovation research and development. Greater product selection for clients, meeting a range of patient requirements throughout the cancer treatment process.
|
Attribute |
Details |
|
Forecast Period |
2023 to 2030 |
|
Historical Data Available for |
2018 to 2022 |
|
Market Analysis |
US$ Million for Value |
|
Key Regions Covered |
|
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon request |
By Type:
By Application:
By End User:
By Region:
To know more about delivery timeline for this report Contact Sales
The market is anticipated to grow at a CAGR of 10.7% during the projected period.
The hadron therapy market was valued at USD 5,111.3 million in 2023.
The United States held the largest market share in 2023.
The prominent players in the market are Koninklijke Philips N.V., IBA Worldwide, Advanced Oncotherapy, Varian Medical Systems, Inc., Optivus Proton Therapy, Inc., Hitachi, Ltd., Sumitomo Corporation, Mevion Medical Systems, ProNova Solutions, LLC, ProTom International Mitsubishi Electric Corporation, Elekta, and others.
The proton beam segment is expected to grow fastest during the forecast period.
